PSTV spiked +40% after UnitedHealthcare agreed to cover CNSide, a diagnostic test for tumor cells in cerebrospinal fluid.
Reddit's penny stock community is debating whether the deal is a sustainable revenue driver or short-term hype.
CNSide is PSTV's first commercial product, with strong sensitivity/specificity numbers and a track record in over 11,000 tests.
Plus Therapeutics (![]()
The Catalyst: UnitedHealthcare Coverage
On ![]()
Reddit users on r/10xPennyStocks highlighted the deal as a potential turning point. One post titled "Thoughts on PSTV after the UNH deal?" noted the stock's +40% spike and asked whether the coverage could sustain revenue growth or was merely a hype catalyst. The community weighed in with 18 comments and 24 upvotes, reflecting a mix of bullish enthusiasm and cautious skepticism.
Penny Stock Community Buzz
Beyond the specific PSTV deal, the broader r/pennystocks subreddit has seen elevated activity, with 105 posts, 1,702 upvotes, and 1,412 comments on September 30. The average sentiment across these discussions was moderately bullish at 0.595. Meanwhile, a separate thread on r/10xPennyStocks asked how users discover stocks before they "rocket," using PSTV as an example. The author expressed concern about potential bots promoting already-inflated stocks, signaling a wary undercurrent even amid the excitement.
PSTV ranked third among all tickers in Reddit discussion score on September 30, with 6 posts, 87 comments, and 224 upvotes. Its sentiment score of 0.683 (bullish) was notably high, reflecting optimism tied directly to the UNH deal.
What's Next for PSTV?
With CNSide now commercially backed by a major insurer, PSTV's path to revenue generation is clearer than before. However, much depends on adoption beyond Texas and UnitedHealthcare, as well as the company's ability to secure additional coverage agreements. Reddit's penny stock crowd will be watching closely, especially given the stock's volatility and the broader skepticism about pump-and-dump dynamics.
Subscribe to Tendie.bot for more market recaps.
